Ads by Google
The combination of blood test and a number of symptoms increase ovarian cancer detection accuracy by 20 percent.
BiPar Sciences announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug resistant xenograft models of ovarian cancer.
The FAS-detect IHC test was used in evaluating 321 samples of serous ovarian cancer.
BioNumerik Pharmaceuticals initiates global Phase III clinical trial of BioNumerik's anticancer drug candidate known as Karenitecin in advanced ovarian cancer patients. BioNumerik is developing Karenitecin (also known as BNP1350) as an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. Based on prior studies, BioNumerik believes Karenitecin has the potential for fewer side-effects, better efficacy, and less susceptibility to drug resistance mechanisms compared to the currently marketed camptothecin drugs.
Northwest Biotherapeuticsannounced that a Phase I/II clinical trial in at least 30 patients, using DCVax-L for recurrent ovarian cancer, has begun
Scientific team has found that the elevated levels of certain proteins typically associated with keeping cancer cells alive may actually correspond with improved patient survival in ovarian cancer.
Frequent consumption of foods containing the flavonoid kaempferol, including non-herbal tea and broccoli, was associated with a reduced risk of ovarian cancer.
Vermillion presented data demonstrating that several of Vermillion's ovarian cancer protein biomarkers could be used to detect early-stage ovarian cancer and to predict survival. These poster presentations were made at the 15th International Meeting of the European Society of Gynecological Oncology (ESGO) in Berlin, Germany.
Phase 2 Consortium clinical trial shows promising results for ovarian cancer treatment in platinum-resistant ovarian cancer patients.
Researchers have discovered that a specific mutation of the COX2 gene seems to play a role in the onset of ovarian cancer, increasing women's susceptibility to developing ovarian cancer.
Access Pharmaceuticals, Somanta Pharmaceuticals announced new data emerging from a pre-clinical collaboration with Imperial College London suggests that Somanta's Angiolix could be effective in the treatment of ovarian cancer.
More than one-third of Canadian women believe that human papillomavirus vaccines prevent ovarian cancer.
Scientists may have discovered the perfect model for potentially developing early detection of ovarian cancer; the chicken.
Studies show encouraging results in detecting early-stage ovarian cancer in high-risk groups of women.
The "real value" of recommendations released last week for identifying symptoms that could signal early stages of ovarian cancer might be to "raise awareness" of the disease among physicians and their patients.
Ovarian Cancer Institute in Atlanta echoes findings in a report issued from the American Cancer Society, Gynecologic Cancer Foundation and the Society of Gynecologic Oncologists.
National Ovarian Cancer Coalition joins the Gynecologic Cancer Foundation and other national organizations in announcing the first national agreement on ovarian cancer symptoms.
Ciphergen Biosystems Inc. presented data on the discovery of several protein biomarkers that may be potential diagnostic markers in detection of early-stage ovarian cancer.